Keywords: Isis Pharma, R&D pipeine, Obesity, Cancer, ISIS-FGFR4Rx, ISIS-STAT3Rx

Potential obesity and cancer drugs added to Isis Pharma development pipeline

Article | 07 January 2011

Print This

USA-based antisense drug discoverer and developer Isis Pharmaceuticals (Nasdaq: ISIS) revealed yesterday that it has added two new drugs to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in